Navigation Links
BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
Date:6/19/2013

Bloomington, Indiana (PRWEB) June 19, 2013

BioConvergence team members Curtis Strother and Désirée Valentine joined the speaking faculty at 2013’s BioLogistics Summit in San Francisco earlier this month.

The conference, coordinated by Cold Chain IQ and IQPC, addressed the increasingly complex logistical issues surrounding biologics. This “complexity” is, in part, attributed to current trends of globalization, outsourcing, and personalized medicine.

“Implicit within these trends is an increase in movement, which is often associated with quality and product integrity issues,” according to Strother, Senior Technical Services Scientist & Project Manager at BioConvergence.

“To avoid these issues, it is important to design a custom transportation strategy for your biosample that will minimize risk of degradation in a cost-effective manner. During our presentation, we introduced a risk matrix for biosamples that we developed to help organizations make informed logistical decisions based on the unique attributes of their biosamples,” Strother relates.

The matrix evaluates biosamples on four parameters: storage/shipping temperature, shipping destination, type of sample, and sample stability. The risk-reduction recommendations that BioConvergence then applies to its shipments are based on best practices guiding relatable temperature-sensitive products within the pharmaceutical industry.

“More than anything, this matrix guides our organization in having a targeted discussion surrounding the risks that biosamples are exposed to and what measures we can take to achieve an acceptable level of risk-tolerance,” adds Valentine, Senior Supply Chain Manager and Business Alliance Manager at BioConvergence.

To learn more about minimizing risk to biosamples and to access the full presentation, please visit http://www.bioc.us/biologistics2013.

An expanded discussion of BioConvergence’s recommended temperature-controlled shipping strategies will take place this fall during the 11th Annual Cold Chain GDP & Temperature Management Logistics Global Forum when Valentine and Associate Process Engineer, Travis Hudson, will conduct a discussion on key findings discovered through international shipment case studies.

About BioConvergence
BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, they have over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. Their unique E-Transparency® System provides transparency and flexibility to their clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.BioC.us.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10848632.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioConvergence® Launches New Blog Aimed at Exploring Best Practices of Pharmaceutical and Biotechnology Industries
2. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
3. SACHEM Presents ZeoGen™ Structure Directing Agents at the 17th Annual IZC in Moscow
4. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
5. JULABO USA Inc. Presents the New PRESTO® W91 and W92 Series of Highly Dynamic Temperature Control Systems
6. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
7. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
8. Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
9. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
10. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
11. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):